Merck Sharp + Dohme Corp.

Medshine Discovery Inc.

Wuxi Biocity Biopharmaceutics Co., Ltd.

Shijiazhuang Sagacity New Drug Development Company, Ltd.

Merck Sharp + Dohme B.v.

Harbin Pharmaceutical Group Co., Ltd. General Pharmaceutical Factory

Chinese Pla General Hospital

Chundao Yang

Jian Li

Shuhui Chen

Xin Li

Hao Wu

Jian Liu

Wenyuan Qian

Shilan Liu

Sobhana Babu Boga

Joseph A Kozlowski

Xiaolei Gao

Jie Li

Deodial Guy Guiadeen

Zhengwei Li

Wensheng Yu

Younong Yu

Yunfu Luo

Ronald M Kim

Rajan Anand

Dahai Wang

Jiaqiang Cai

Guoping Hu

Maoyi Lei

James Han Wang

Alan B Cooper

Ying-Duo Gao

Tjeerd Barf

Brian M Andresen

Adrianus Petrus Antonius De Man

Ling Liu

Allard Kaptein

Chen Li

Abdul-Basit Alhassan

Hugh Y Zhu

Oleg B Selyutin

Henry M Vaccaro

Arthur A Oubrie

Christiaan Gerardus Johannes Maria Jans

Hongjian Wang

Deodialsingh Guiadeen

Johannes Bernardus Maria Rewinkel

Jacobus C H M Wijkmans

Kunlun He

Hans C A Raaijmakers

Chunlei Liu

Guanghai Xu

Xin Yao

Guoqiang Dai

Jan-Gerard Sterrenburg

Zeyu Zhang

Shujie Yuan

Shuling Zheng

Xiaojian Gao

Jiaji Liu

Tao Wei

Mingda Sun

Daoxu Zhang

Jinlong Zhao

Xinchun Yang

Jyhshing Wang

Lanbao Sun

Huanan Zhao

James Wang

Tjeerd A Barf

Jacobus CHM Wijkmans

Johannes BM Rewinkel

Christiaan GJM Jans

Adrianus PA De Man

Yiwei Wang

Hans CA Raaijmakers

Disclosed is a crystal form of a compound of formula (I) and the use of the crystal form in the preparation of a drug for treating Wee1-related diseases.

Crystal form of Wee1 inhibitor compound and use thereof

A pyrimidopyrazolone derivative as a Wee1 inhibitor and use thereof in preparation of a medicament for treating Wee1-related diseases are described. In particular, the present invention relates to a compound of formula (I), an isomer or a pharmaceutically acceptable salt thereof.

Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof

Disclosed in the present invention are a macrocyclic compound serving as a Weel inhibitor, and applications thereof in the preparation of drugs for treating Weel-related diseases. The present invention specifically relates to a compound represented by formula (II), an isomer thereof, and a pharmaceutically acceptable salt thereof. 

Macrocyclic compound serving as Wee1 inhibitor and applications thereof

The present invention relates to a class of isoindolinone derivatives and use thereof in the preparation of a medicament for treating diseases associated with a novel colony stimulating factor 1 receptor (CSF-1R) inhibitor. In particular, the present invention relates to a compound of formula (I) and a pharmaceutically acceptable salt thereof or a stereoisomer thereof. 

Heterocyclic compound as CSF-1R inhibitor and use thereof

A compound represented by formula (I) or an isomer or a pharmaceutically acceptable salt thereof. The present invention also relates to an application of the same in preparing a drug for treating a disease related to a PGIreceptor. 

Prostacyclin receptor agonist

Disclosed are a series of quinolino-pyrrolidin-2-one compounds, and application thereof in preparation of drugs for ATM inhibitor-related diseases. The present disclosure specifically relates to a derivative compound represented by formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof. 

Quinolino-pyrrolidin-2-one derivative and application thereof

The present invention provides a 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one compound having an inhibitory effect on Wee1, and includes an application of the compound in treating various types of tumors. 

1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor

Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof. 

PDE4 inhibitor

Provided are a phosphodiesterase-4 (PDE4) inhibitor and application thereof in preparation of a medication for treating a disease related to PDE4. Specifically disclosed is a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof. 

Cyclic compound acting as PDE4 inhibitor

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders. 

Btk inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders. 

Tertiary alcohol imidazopyrazine BTK inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders. 

BTK inhibitors

Benzamide imidazopyrazine Btk inhibitors

Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.

Diaza-benzofluoranthrene compounds

Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders. 

BTK Inhibitors

Growing community of inventors

Shanghai, China

Chundao Yang